Change In Prescription Form Brings Changes To Japan’s Generic Drug Industry
This article was originally published in PharmAsia News
Executive Summary
The change in remuneration for medical services starting in April could greatly impact the generic drug industry in Japan. A new prescription form will provide that pharmacies can make substitutions unless a doctor specifically requests that a generic or substitution drug cannot be prescribed. Currently, substitutions are difficult except for some extreme situations. Pharmacies can substitute among various generic drugs, and procure from multiple brands thus reducing the need for surplus inventories. Branding will be vital for makers, along with price. Major players that have an enhanced product lineup may have a strong advantage. Foreign generic drug giants such as Teva, Sandoz, Mylan Laboratories and Lupin, which bought Osaka-based Kyowa Yakuhin last year, will be closely watched. (Click for more-Japanese language
You may also be interested in...
MHLW Reports Little Progress In Japan’s Generic Drug Use
Ministry of Health Labor and Welfare Minister Yoichiro Masuzoe and Treasury Minister Shoichi Nakagawa Dec. 18 announced a plan of reducing ¥220 billion in social insurance growth for fiscal year 2009, in which the real reduction will come from ¥23 billion as a result of generic drug use. However, a report released Dec. 15 by MHLW painted a discouraging picture of generic drug use in Japan, even amidst several pushes from the ministry to promote usage during the year.
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.